1 Can we predict antibody responses in SARS-CoV-2? A cohort

2 analysis.

3 Running title: Predict SARS-Cov-2 antibody response

4 Authors:

- 5 Mary Gaeddert (1), Philip Kitchen (1), Tobias Broger (1), Stefan Weber (1), Ralf
- 6 Bartenschlager (2), Anna Plaszczyca (2), Hans-Georg Kräusslich (3), Barbara Müller
- 7 (3), Margarida Souto-Carneiro (4), Maike Janssen (4), Carsten Müller-Tidow (4), Uta
- 8 Merle (5), Yannis Herrmann (1), Lukas Raedeker (1), Jakob Sebastian (1), Niall
- 9 Brindl (1), Tim Starck (6), Claudia M. Denkinger (1)

10

11 Author affiliations:

- 12 1. Division of Tropical Medicine, Center of Infectious Diseases, Heidelberg
- 13 University Hospital, Germany
- 14 2. Department of Infectious Diseases, Molecular Virology, Heidelberg University
- 15 Hospital, Heidelberg, Germany
- 16 3. Virology, Center of Infectious Diseases, Heidelberg University Hospital,
- 17 Heidelberg, Germany
- 18 4. Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg,
- 19 Germany.
- 20 5. Department of Gastroenterology, Heidelberg University Hospital, Germany
- 21 6. Heidelberg Institute of Global Health, Heidelberg University Hospital, Heidelberg,
- 22 Germany

23 **Corresponding author:**

- 24 Claudia M. Denkinger, <u>Claudia.Denkinger@uni-heidelberg.de</u>, Phone: 0049 6221 56-
- 25 22999, Fax: 0049 6221 56-5204
- 26 Abstract word count: 200/200
- 27 **Text word count**: 2,799/3,500
- 28

29 Abstract

Background: After infection with severe acute respiratory syndrome coronavirus (SARS-CoV-2), Immunoglobulin G (IgG) antibodies and virus-specific neutralizing antibodies (nAbs) develop. This study describes antibody responses in a cohort of recovered COVID-19 patients to identify predictors.

34

Methods: We recruited patients with confirmed SARS-CoV-2 infection from Heidelberg, Germany. Blood samples were collected three weeks after COVID-19 symptoms ended. Participants with high antibody titers were invited for follow-up visits. IgG titers were measured by the Euroimmun Assay, and nAbs titers in a SARS-CoV-2 infection-based assay.

40

Results: 281 participants were enrolled between April and August 2020 with IgG testing, 145 (51.6%) had nAbs, and 35 (12.5%) had follow-up. The median IgG optical density (OD) ratio was 3.1 (Interquartile range (IQR) 1.6-5.1), and 24.1% (35/145) had a nAb titer>1:80. Higher IgG titers were associated with increased age and more severe disease, and higher nAbs were associated with male gender and

46	CT-value of	25-30 on	RT-PCR at	diagnosis.	The median	IgG O	D ratio	on follow-up
----	-------------	----------	------------------	------------	------------	-------	---------	--------------

- 47 was 3.7 (IQR 2.9-5.9), a median increase of 0.5 (IQR -0.3-1.7). Six participants with
- 48 follow-up nAbs all had titers \leq 1:80.
- 49
- 50 Conclusions: While age and disease severity were correlated with IgG responses,
- 51 predictive factors for nAbs in convalescent patients remain unclear.
- 52
- 53 Keywords: antibody, IgG, neutralizing antibodies, seroconversion, SARS-CoV-2,
- 54 COVID-19
- 55
- 56

57 Introduction

An understanding of the robustness of the antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its longevity is critical to determine the necessary levels and duration of antibody titers that confer protection against re-infection.

62

63 After infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-64 2), about two thirds of hospitalized patients show IgG seroconversion within the first 65 two weeks of infection [1] while later it will be up to 90% [2]. In contrast for mild 66 cases, seroconversion might only be observed in 48% [2]. Previous studies in 67 hospitalized patients with Coronavirus disease 2019 (COVID-19) indicate some 68 correlation between disease severity and strength of the antibody response [3-6]. 69 Also, studies have reported varying results regarding the change of IgG antibodies 70 over time, with some evidence that this time course may also be related to disease 71 severity [6-8].

72

Virus-specific neutralizing antibodies (nAbs) have the ability to inhibit virus replication in an ongoing infection and are likely to play a role in preventing re-infection. It has been shown that SARS-CoV-2 infection can result in the production of antibodies with neutralizing properties in vitro and protective effects in animal models [9]. However, the precise correlation between IgG levels and nAb response [10], as well as the predictors of nAbs in an effective and durable immune response against SARS-CoV-2 [9, 11] have not been clarified. Similar to IgG levels, nAbs may

80 decrease several months after infection, but tend to remain higher following 81 symptomatic infection compared with asymptomatic [8].

82

Understanding the levels of IgG and nAbs that are relevant for protection is also important for the use of convalescent plasma in the treatment of SARS-CoV-2. Convalescent plasma has already been authorized by the FDA under Emergency Use Authorization [12, 13], however the impact on patient outcomes has been variable [14, 15]. There is therefore also an urgent need to identify factors that predict which convalescent patients will have robust immune responses to SARS-CoV-2 infection and be suitable to serve as plasma donors.

90

The aim of this study is to describe the antibody response in a cohort of recovered COVID-19 patients and identify predictors of total IgG and neutralizing antibody responses. The results will be useful in identifying the most suitable plasma donors and may further contribute to understanding the risk for future re-infection.

95

96 Methods

97 Study design and participants

98 Convalescent COVID-19 patients from the Rhein-Neckar region surrounding
99 Heidelberg, Germany, were recruited for this study. Participants were identified by
100 the local Public Health Authority as meeting the current guidelines for COVID testing
101 (exposure to a SARS CoV-2 positive case, suggestive symptoms, or travel to a risk

102 area) and were tested in a certified test center in the Heidelberg area. Those who 103 tested positive for SARS-CoV-2 infection were contacted approximately two to three 104 weeks after the positive test and asked to participate in the study. A survey 105 conducted online or by telephone collected retrospective data on demographic and 106 clinical information, including symptoms, hospitalization, and measures of COVID-19 107 disease severity. After survey completion, participants were screened for potential 108 plasma donation. The inclusion criteria for plasma donation were age less than 65 109 years and no comorbidities. Participants from outside the Rhein Neckar region were 110 also recruited through a public advertisement of the COVID-19 plasma donor 111 program. These participants followed the procedures below but did not complete the 112 survey and are missing the demographic and clinical information.

113

The first study visit was conducted at the Heidelberg University Hospital at least three weeks after symptoms ended. During this visit, a nasopharyngeal swab and blood samples were collected for testing as described below. Convalescent patients with high IgG levels (optical density (OD) ratio > 2.5) and a nAbs titer (> 1:80) were invited to participate as plasma donors. Serologic testing was performed again at the time of plasma donation.

120

All procedures were performed in accordance with the ethical standards of the institutional research committee of Heidelberg University (study approval number S686/2018). Written informed consent was obtained from each participant.

125 Molecular Assays

Nasopharyngeal swabs (eSwabs, Copan) were analyzed with Allplex 2019-nCoV Assay (Seegene Inc, Seoul, South Korea) and Tib-Molbiol 2019-nCoV LightMix (TIB Molbiol, Berlin, Germany) for viral RNA using reverse-transcriptase polymerase chain reaction (RT-PCR) designed to detect RdRP and N genes specific for SARS-CoV-2 and the E gene for all of Sarbecovirus including SARS-CoV-2. Cycle thresholdvalues (CT-values) under 38 were considered positive.

132

133 Serological Assay

134 Enzyme linked immunosorbent assay (ELISA) measurements for determination of IgG reactivity against the S1 domain of the viral spike (S) protein were carried out 135 136 using the Euroimmun Anti-SARS-CoV-2-ELISA (IgG) (EI 2606-9601 G; 137 EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany) test kit according to the manufacturer's protocol. Samples were processed on an 138 139 Euroimmun Analyzer I instrument according to the manufacturer's instructions. 140 Immunoreactivity was determined by measuring the optical density at 450 nm 141 (OD450) and divided by the OD450 of a calibrator comprised in the kit to minimize 142 inter-assay variation. The interpretation of the semi-quantitative ratiometric values 143 obtained followed the manufacturer's test instructions: ratios <0.8 were classified as negative, 0.8-1.1 as borderline, and \geq 1.1 or higher as positive. Sera with an OD ratio 144 145 >2.5 were tested for the presence of neutralizing antibodies. A subset of samples 146 was also tested with an ELISA assay targeting viral nucleocapsid antigen using the EDI[™] Novel Coronavirus COVID-19 IgG ELISA Kit (Epitope Diaganostics Inc, San 147

Diego CA, USA), according to the manufacturer's instructions. Samples were analyzed in the SpectraMax M2^e multi-detection microplate reader (Molecular Devices, USA) at 450nm. Samples with an O.D. at 450nm ≥0.22 were considered positive. To minimize inter-assay variation the O.D. values were divided by the kit's internal calibration control. The interpretation of the semi-quantitative ratiometric values was carried out similarly as for the S1 domain of the viral spike protein.

154

155 *Neutralization assay*

VeroE6 cells were seeded into 96-well plates one day before the assay. Serial 156 157 dilutions of sera starting from a 1:10 dilution were prepared in OptiMEM 158 (ThermoFisher Scientific, Waltham, MA, USA) in a final volume of 75 µl and incubated with ~24,000 PFU of SARS-CoV-2 (BavPat1/2020 strain, European Virus 159 Archive) per well for 1 hour at 37 °C in a final volume of 150 µl. One third of each 160 161 serum-virus mixture (50 µl) was then used for infection (final MOI ~0.25). Infections 162 were performed in duplicates. At 20 hours post-infection, cells were fixed with 5% 163 formaldehyde and immune-stained using a primary mouse antiserum binding to 164 double-stranded RNA, a viral replication intermediate (J2 mouse antibody; Scicons, 165 Szirák, Hungary) and a secondary anti-mouse horseradish peroxidase-coupled 166 antibody (Merck, Darmstadt, Germany). The signal was developed using the KPL 167 SureBlueTM TMB peroxidase substrate (Seracare, Milford, MA, USA) and measured 168 in a plate reader at a wavelength of 450 nm. Data were normalized to no-serum 169 control (100%) and mock-infected control (0%). The neutralization (NT) titer was

defined as the highest serum dilution resulting in more than 50% reduction of thenormalized signal.

172

173 Statistical Analysis

174 We assessed factors associated with antibody response by analyzing demographic 175 and clinical characteristics of participants with different levels of IgG and nAbs. Linear 176 regression was performed to determine the association of demographic and clinical 177 characteristics with IgG antibody titers as a continuous outcome. Logistic regression 178 was performed to study the association of the same covariates with nAbs as a 179 categorial outcome. For both regression analyses, factors with a p-value <0.1 in the 180 univariate analysis were included in the multivariable model, and retained in the model if the p-value was <0.05 using manual backward elimination. IgG titers from 181 182 convalescent and follow-up samples were compared using the Wilcoxon matched-183 pairs signed-ranks test. Analysis was performed using Stata version 15.1 (StataCorp 184 LLC. College Station, TX).

185

186 Definitions

The first swab collected by the Public Health Authority for initial diagnosis of SARS-CoV-2 infection is referred to as the 'diagnostic swab', and the second swab collected at the screening visit for plasma donation is referred to as the 'convalescent swab'. An IgG OD ratio <1.1 was defined as negative, 1.1 to 2.5 as weak positive, and >2.5 as high positive. NAbs were categorized into high and low, with titers \leq 1:80

defined as low and >1:80 as high by expert consensus after review of data from aninpatient cohort.

194

An illness severity score was created using a combination of self-reported activity restriction, the presence of COVID-19 symptoms indicative of severe disease (cough, fever, or dyspnea), and hospitalization. The categories were defined as mild illness (normal activity, none of the three symptoms, and not hospitalized), moderate illness (restricted activity, symptomatic, and not hospitalized), and severe illness (severely restricted activity, symptomatic, and hospitalized).

201

202 **Results**

203 A total of 281 participants were enrolled between April and August 2020. Survey 204 responses were available for 200 (71.2%) participants. The population was 55% 205 (107/194) male with a median age of 39 ([Interguartile range] IQR 29-50) (Table 1). 206 Only 3/171 (1.8%) participants were hospitalized, with one in intensive care. The 207 median CT-value at the time of diagnosis was available for 165/281 and was 25 (IQR 208 20 to 28). IgG testing was performed for all 281 participants and of these, ODs were 209 >2.5 in 145 (51.6%). Thirty-five participants (12.5%) had serology repeated at the 210 time of plasma donation.

211

212 Convalescent samples were collected from all participants a median of 34 days (IQR 213 28-43) after the diagnostic swab and 29 days (IQR 22 to 37) after the end of

214 symptoms. The median IgG OD ratio at the convalescent visit was 3.1 (IQR 1.6 to 215 5.1), with 58.7% (165/281) of participants categorized as having a highly positive 216 antibody response, 26.0% (73/281) with a positive response, and 15.3% 43/281 217 (15.3%) with a negative or borderline IgG antibody response. Only 24.1% of the 218 tested participants (35/145) displayed a nAb titer >1:80. All three hospitalized 219 participants displayed nAb titers of 1:160. The convalescent swab was positive by 220 RT-PCR in 9.1% (25/274) of participants and the median CT value was 37 (IQR 35 to 221 38). Of those who had a positive convalescent swab, 25% (5/20) had nAbs >1:80.

222

223 The IgG convalescent titer was highest in adults 18 to 29 years old, decreasing in 30-224 to 44-year-olds, and increasing again in adults 45 to 60 years of age (Table 2 and 225 Figure 1). The nAbs titers, in contrast, did not show a statistically significant change 226 by age (Table 3 and Supplemental Figure 1). There was a correlation between 227 increasing IgG titer and nAbs titer although Kappa was low (OR=1.6 ([95% 228 Confidence Interval] 95%CI 1.3-1.9), p<0.001, Kappa=0.095) (Figure 2). The IgG OD 229 ratio of convalescent sera was neither correlated with the CT-value of the diagnostic 230 swab (p=0.666) (Supplemental Figure 2) nor with that of the convalescent swab 231 (p=0.727).

232

The results of the multiple linear regression model on 200 patients with IgG results and information from the survey showed that higher IgG antibody titers were associated with age 45 to 60 years (0.8, 95%Cl 0.05-1.6, p=0.036), compared to age 30 to 44) and moderate/severe activity restriction (2.1, 95%Cl 1.2-3.0, p<0.001), 11

compared to normal activity) (Table 2). A similar analysis carried out on the 120
participants with survey results and nAb titers showed that male gender (2.2, 95% CI
0.9-5.6, p=0.097, compared to female) and a CT-value of 25-30 (4.9, 95%CI 0.925.8, p=0.062, compared to CT-value>30) from the diagnostic swab were associated
with high nAb titers in the univariate logistic regression model at the 0.1 level (Table
3 and Supplemental Figure 3).

243

For the 63 participants tested with the nucleocapsid protein ELISA, IgG levels were classified as negative for 24 (38.1%), 11 (17.5%) as weak positive, and 28 (44.4%) as high positive. The correlation between the spike protein and nucleocapsid protein assays was 73.0% (Kappa=0.548) and the nucleocapsid assay and nAbs was 16.7% (Kappa=0.022) (Supplemental Figure 4).

249

250 The illness severity score was analyzed separately as it combined multiple variables 251 that were already included in the regression models. Based on the categories 252 outlined above, 32.3% (52/161) were defined as mild, 54.0% (87/161) as moderate, 253 and 13.7% (22/161) as severe illness. Participants with severe disease had median 254 IgG titers of 6.0 (IQR 3.8 to 7.6), compared to 2.5 (IQR 1.4 to 4.1) for those with mild 255 disease and 2.9 (IQR 1.5 to 4.7) for moderate disease (p<0.001). For nAbs, we 256 observed a trend that participants with more severe disease had high titers, but the 257 difference was not statistically significant (OR 1.9, 95%CI 0.9-3.8, p=0.084).

258

The 35 participants eligible for the follow-up testing had the second blood collection a median of 46 days (IQR 23 to 57) after the convalescent testing. The median IgG OD ratio was 3.7 (IQR 2.9 to 5.9), and 74.3% (26/35) were categorized as having a high positive IgG response. The IgG titers showed a median increase of 0.5 (IQR -0.3 to 1.7) from convalescent to follow-up testing (p<0.001) (Table 1 and Figure 3). The nAbs titers from the six follow-up participants were all \leq 1:80 (Figure 4).

265

266 Discussion

267 This study describes the antibody response in a cohort of 281 recovered COVID-19 268 patients. Our results show that older age (45-65 years) and more severe disease 269 were associated with a stronger IgG response. This response was sustained up to 47 270 days after the convalescent sample in those who had a follow-up visit. However, 271 there was poor correlation between clinical characteristics and the strength of a neutralizing antibody response. Furthermore, in the few participants that had nAbs 272 273 follow-up testing, a reduction in the neutralization capacity of the circulating IgG 274 antibodies was observed. The persistence of nAbs over time must be confirmed in 275 future studies with larger cohorts.

276

We found 15.3% of patients not to have an antibody response at initial testing. This finding is similar to a finding in a study of over 1,300 SARS-CoV-2 patients in New York City that reported IgG seroconversion to the S protein in 89% PCR-positive patients at the time of initial testing from Wajnberg et al. Our observation of the IgG response being correlated with age and disease severity confirms the findings of a 13

prior study by Klein et al, where older age and hospitalization was associated with stronger anti-SARS-CoV-2 antibody response quantified by both IgG levels against the S protein and nAb titers [10]. In this study of 126 plasma donors, male sex and older age were also observed to be associated, however we were only able to deduce an association of nAbs but not IgG levels with male sex.

287

While our study showed persistence of an IgG response after a month and a half in those with high initial IgG titers, a study of 365,000 adults in England by Ward et al. showed a decline in the prevalence of SARS-CoV-2 antibodies over the course of three months. The decline in IgG positivity was greatest among those who reported no symptoms, a population that was underrepresented in our study [16].

293

294 These findings have implications for the selection of convalescent donors of plasma 295 for plasma therapy [13]. Thus, in order to improve the anti-SARS-CoV-2 IgG titers 296 present in the donated plasma, donors should be selected from those with a more 297 severe course of COVID-19 disease and asked to donate plasma as soon as 298 possible after convalescence [10, 17]. Furthermore, these findings might have 299 implications for immunity against repeat infections. However, further data is needed 300 to understand whether antibodies or T cells confer protective immunity to SARS-301 CoV-2.

302

At the convalescent study visit, 9% of participants remained positive for SARS-CoV-2 on PCR. However, all CT-values were >30, indicating a low viral load and likely nonviable virus particles. These data are in line with other studies reporting positive PCR results up to 28 days and longer after symptom resolution [3, 18-20]. Surprisingly, persistent viral shedding was not associated with IgG or nAbs response in our analysis, supporting the idea that shed RNA is not an indicator of ongoing infection [3, 8].

310

311 This study has several limitations. The criteria for plasma donation restricted 312 participation to healthy people under 60 years of age. Further, the survey responses 313 showed that most participants had relatively mild COVID-19 disease, although 314 asymptomatic participants were underrepresented and very few were hospitalized. 315 These factors indicate that the results may not be generalizable to populations who 316 are older than 60, have severe disease, have comorbidities, or to asymptomatic 317 patients. Most participants only had one serum sample collected, so there is limited 318 data on the change in antibody titers over time. The variability in the nAb response 319 would require evaluation of larger numbers of convalescent patients in order to yield 320 a better understanding of predictive factors.

321

This study also has several strengths. We present the IgG response in over 200 participants and nAbs in 145 participants. We also collected follow-up data for those participants who had a strong IgG and nAbs response at baseline. The information

- 325 on illness severity and PCR results from both diagnosis and convalescent time-points
- 326 provided a fuller clinical picture.
- 327

328 Conclusion

- 329 While older age and disease severity were correlated with stronger IgG responses,
- 330 the predictive factors for strong neutralizing antibody response in convalescent
- 331 patients remain unclear.

332 Footnote page:

- 333 **Conflict of interest**: The authors declare that they have no competing interests.
- **Funding:** This work was supported by the German Federal Ministry of Education and
- Research (BMBF) program on emergency research funding for COVID-19 (funding
- number 01KG20152) and internal funds of Heidelberg University Hospital.
- 337 **Corresponding author:**
- 338 Claudia M. Denkinger
- 339 Address: Section of Clinical Tropical Medicine, Center for Infectious Disease,
- 340 Heidelberg University Hospital, Im Neuenheimer Feld 324, Heidelberg 69120,
- 341 Germany
- 342 Telephone: 0049 6221 56-22999; Fax: 0049 6221 56-5204
- 343 <u>Claudia.Denkinger@uni-heidelberg.de</u>

344 Author contributions: CMD was responsible for the conceptualization and design of 345 the study and supervised the analysis and writing. MG was responsible for the 346 statistical analysis and writing. CMT, PK and TB were responsible for the literature 347 review and supported the conceptualization and design of the study. PK, YH, LR, JS, 348 MJ, NB, and TS were responsible for the survey and patient recruitment. SW and MJ 349 were responsible for the study visits and blood collection. HGK, RB, MSC, BM and 350 AP were responsible for the antibody testing. All authors contributed to data 351 interpretation, critically reviewed the first draft, and approved the final version and 352 agreed to be accountable for the work.

353 **Ethical Approval**: All procedures performed in studies involving human participants 354 were in accordance with the ethical standards of the institutional research committee

- of Heidelberg University (S686/2018) and with the 1964 Helsinki declaration and its
- 356 later amendments or comparable ethical standards.
- 357 **Acknowledgements:** We would like to thank all the participants who contributed to
- the survey and plasma donation study. We are grateful to Maria Anders-Össwein,
- 359 Stefanie Wolf, and Ira Pistorius for their dedicated expert technical assistance.

360 **References**

- 1. Xiang F, Wang X, He X, et al. Antibody Detection and Dynamic Characteristics in
- 362 Patients With Coronavirus Disease 2019. Clinical infectious diseases : an official
- publication of the Infectious Diseases Society of America **2020**; 71:1930-4.
- Imai K, Kitagawa Y, Tabata S, et al. Antibody response patterns in COVID-19
 patients with different levels of disease severity—Japan. medRxiv
 2020:2020.11.20.20231696.
- 367 3. Tan W, Lu Y, Zhang J, et al. Viral Kinetics and Antibody Responses in Patients
 368 with COVID-19. medRxiv **2020**:2020.03.24.20042382.
- 4. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in
 posterior oropharyngeal saliva samples and serum antibody responses during
 infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious
 Diseases 2020; 20:565-74.
- 5. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of
 novel coronavirus disease 2019. Clinical Infectious Diseases 2020.
- 375 6. Chen Y, Zuiani A, Fischinger S, et al. Quick COVID-19 Healers Sustain Anti-
- 376 SARS-CoV-2 Antibody Production. Cell **2020**; 183:1496-507.e16.
- 377 7. Iyer AS, Jones FK, Nodoushani A, et al. Dynamics and significance of the antibody
- 378 response to SARS-CoV-2 infection. medRxiv **2020**:2020.07.18.20155374.
- 8. Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of
- asymptomatic SARS-CoV-2 infections. Nature Medicine **2020**; 26:1200-4.
- 381 9. Bao L, Deng W, Gao H, et al. Reinfection could not occur in SARS-CoV-2 infected
- 382 rhesus macaques. bioRxiv **2020**:2020.03.13.990226.

383	10. Klein S	L, F	eko	osz A, Park	H-S, et al. Sex,	age, and	hospita	alization drive	antibody
384	responses	in	а	COVID-19	convalescent	plasma	donor	population.	medRxiv
385	2020 :2020.	.06.2	26.2	20139063.					

- 386 11. Ju B, Zhang Q, Ge X, et al. Potent human neutralizing antibodies elicited by
 387 SARS-CoV-2 infection. bioRxiv **2020**:2020.03.21.990770.
- 12. Valk SJ, Piechotta V, Chai KL, et al. Convalescent plasma or hyperimmune
- immunoglobulin for people with COVID-19: a rapid review. The Cochrane database
- 390 of systematic reviews **2020**; 5:Cd013600.
- 391 13. Administration UFaD. Recommendations for Investigational COVID-19
- 392 Convalescent Plasma. Available at: <u>https://www.fda.gov/vaccines-blood-</u>
- 393 <u>biologics/investigational-new-drug-ind-or-device-exemption-ide-process-</u>

394 <u>cber/recommendations-investigational-covid-19-convalescent-plasma</u>. 2021.

- 14. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A Randomized Trial of
- 396 Convalescent Plasma in Covid-19 Severe Pneumonia. New England Journal of 397 Medicine **2020**; 384:619-29.
- 15. Libster R, Pérez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to
- Prevent Severe Covid-19 in Older Adults. New England Journal of Medicine 2021;
 384:610-8.
- 401 16. Ward H, Cooke G, Atchison C, et al. Declining prevalence of antibody positivity to
 402 SARS-CoV-2: a community study of 365,000 adults. medRxiv
 403 2020:2020.10.26.20219725.
- 17. Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a
- 405 COVID-19 recovered patient cohort and their implications. medRxiv 406 **2020**:2020.03.30.20047365.

407	18. Wajnberg A, Mansour M, Leven E, et al. Humoral immune response and
408	prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York
409	City region. medRxiv 2020 :2020.04.30.20085613.

- 19. Wang B, Wang L, Kong X, et al. Long-term coexistence of SARS-CoV-2 with
- 411 antibody response in COVID-19 patients. Journal of Medical Virology 2020; 92:1684-
- 412 9.
- 413 20. Zhang G, Nie S, Zhang Z, Zhang Z. Longitudinal Change of Severe Acute
- 414 Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus
- Disease 2019. The Journal of infectious diseases **2020**; 222:183-8.

417 Table 1. Demographic and clinical characteristic of participants with

418 convalescent testing (n=281)

	n/N	%
Demographic	cs	
Age, median [IQR]	39 [29-50]	
Gender		
Male	107/194	55.2
Female	86/194	44.3
Diverse	1/194	0.5
Diagnosis		
CT value of diagnostic swab,	25 [20-28]	
	20 [20-20]	
median [IQR]		
CT value of diagnostic swab		
<25	87/165 ^a	52.7
25-30	54/165	32.7
>30	24/165	14.6
Convalescent te	sting	
Days from diagnosis to		
convalescent testing, median [IQR]	34 [28-43]	
Days from end of symptoms to		

convalescent testing, median [IQR]	29 [22-37]	
Result of convalescent swab		
Negative	249/274	90.9
Positive	25/274	9.1
CT value of convalescent swab if	37 [35-38]	
positive, median [IQR]		
IgG OD ratio, median [IQR]	3.1 [1.6-5.1]	
IgG result		
Negative/Borderline (<1.1)	43/281	15.3
Weak positive (1.1-2.5)	73/281	26.0
High positive (>2.5)	165/281	58.7
Neutralizing Antibodies		
Low (≤1:80)	110/145	75.9
High (>1:80)	35/145	24.1
Neutralizing Antibodies if		
convalescent swab positive		
Low (≤1:80)	15/20	75.0
High (>1:80)	5/20	25.0
Follow-up testing	(N=35)	

Days from convalescent to follow-		
up blood draw, median [IQR]	46 [23-57]	
Follow-up IgG result, median [IQR]	3.7 [2.9-5.9]	
Follow-up IgG result		
Negative/Borderline (<1.1)	2/35	5.7
Weak positive (1.1-2.5)	5/35	14.3
High positive (>2.5)	28/35	80.0
Change in IgG from convalescent	0.5 [-0.3-1.7]	
to follow-up, median [IQR]		
Follow-up Neutralizing Antibodies		
Low (≤1:80)	6/6	100.0

^{419 &}lt;sup>a</sup>Missing data: gender=87, CT value of diagnostic swab=116, result of convalescent swab=7, results of

420 nAbs for convalescent swab-positive=5

421 *participants missing results of the first swab were diagnosed outside of the University Hospital

422 Heidelberg network)

423

424

425 Table 2. Description of factors associated with Convalescent SARS CoV-2 IgG

426 titers (n=200)

Characteristic	Total	OD Ratio,	Simple Linear	Multiple Linear
n/N (%)	population	Median	Regression	Regression
		[IQR]	Coef (95%CI), p-	Coef (95%CI), p-

			value	value			
Demographic							
Age							
18-29	50/200 (25.0)	3.7 [1.9-4.4]	0.1 (-0.8;1.0), 0.829	0.2 (-0.7;1.0), 0.666			
30-44	75/200 (37.5)	2.6 [1.2-4.5]	Reference	Reference			
45-60	75/200 (37.5)	3.6 [1.8-6.3]	0.9 (0.2;1.7), 0.017	0.8 (0.05-1.6), 0.036			
Gender ^a							
Male	107/194 (55.2)	3.1 [1.5-5.1]	0.4 (-0.4;1.0), 0.405				
Female	86/194 (44.3)	3.3 [1.8-4.9]	Reference				
Diverse ^b	1/194 (0.5)	8.4 [8.4-8.4]					
		Clinical					
Activity Restriction							
Normal activity	51/188 (27.1)	2.2 [1.2-3.9]	Reference	Reference			
Minimal restriction	81/188 (43.1)	3.0 [1.8-4.3]	0.5 (-0.3;1.4), 0.187	0.6 (-0.2;1.4), 0.163			
Moderate/Severe	56/188 (29.8)	5.0 [2.6-7.2]	2.2 (1.3;3.1), <0.001	2.1 (1.2;3.0), <0.001			
Symptomatic							
No	4/188 (2.1)	2.5 [0.9-4.0]	Reference				
Yes	184/188 (97.9)	3.2 [1.8-5.1]	1.2 (-1.2;3.7), 0.325				
Fever only							

No	118/192 (61.5)	2.9 [1.5-4.5]	Reference			
	110/192 (01.3)	2.8 [1.3-4.3]				
Yes	74/192 (38.5)	3.5 [2.1-5.9]	0.9 (0.2;1.6), 0.010			
Fever, Dyspnea, or						
Cough						
No	76/192 (39.6)	2.8 [1.6-4.4]	Reference			
Yes	116/192 (60.4)	3.4 [1.9-5.6]	0.7 (0.03;1.4), 0.040			
Symptom duration						
0-10 days	60/200 (30.0)	2.9 [1.6-4.5]	Reference			
11-20 days	87/200 (43.5)	3.5 [2.1-5.7]	0.9 (0.1;1.7), 0.034			
11 20 0033	017200 (40.0)	0.0 [2.1 0.7]	0.0 (0.1,1.7), 0.004			
>20 days	53/200 (26.5)	2.9 [1.4-5.0]	0.2 (-0.7;1.1), 0.731			
Convalescent testing						
		I	1	Γ		
Days from Symptom						
onset to convalescent						
testing	C2/480 (25 0)		Deference			
0-35	63/180 (35.0)	2.6 [1.5-4.9]	Reference			
	89/180 (49.4)	3.4 [2.0-5.5]	0.6 (-0.2;1.4), 0.145			
35-50	28/180 (15.6)	3.5 [1.6-6.4]	0.7 (-0.4;1.8), 0.182			
>50	20,100 (10.0)	0.0 [1.0 0.1]				
CT value of diagnostic						
swab						
<25	79/151 (52.3)	3.3 [2.1-4.9]	-0.1 (-1.2;1.0), 0.880			
	(/					

25-30	48/151 (31.8)	3.6 [1.6-5.8]	0.3 (-0.9;1.6), 0.569	
>30	24/151 (15.9)	3.5 [1.9-4.8]	Reference	
Result of convalescent				
swab				
Negative	177/199 (88.5)	3.0 [1.6-5.1]	Reference	
Positive	22/199 (11.1)	3.8 [2.2-4.7]	0.2 (-0.9;1.2), 0.780	

427 ^aMissing data: gender=6, Activity Restriction n=12; Symptomatic n=12; specific symptoms n=8; start of

428 symptoms n=20; diagnostic swab n=49; convalescent swab n=1

429 ^bDiverse gender (n=1) excluded from regression model

- 430
- 431

432 Table 3. Description of factors associated with Convalescent SARS CoV-2

433 Neutralizing antibody titers (n=120)

Characteristic	Total	Low (≤1:80)	High (>1:80)	Logistic Regression,		
n/N (%)	population			Univariate		
				OR (95% CI), p-		
				value		
Demographic						
		r				
Age						
18-29	31/120 (25.8)	25/90 (27.8)	6/30 (20.0)	Reference		
30-44	40/120 (33.3)	31/90 (34.4)	9/30 (30.0)	1.2 (0.4-3.9), 0.748		

45-60	49/120 (40.8)	34/90 (37.8)	15/30 (50.0)	1.8 (0.6-5.4), 0.269
Gender ^a				
Male	63/116 (54.3)	45/89 (50.6)	18/27 (66.7)	2.2 (0.9-5.6), 0.097
Female	52/116 (44.8)	44/89 (49.4)	8/27 (29.6)	Reference
Diverse ^b	1/116 (0.9)	0	1/27 (3.7)	
	C	Clinical		
A stivity Destriction				
Activity Restriction				
Normal activity	27/114 (23.7)	23/87 (26.4)	4/27 (14.8)	Reference
Minimal restriction	43/114 (37.7)	33/87 (37.9)	10/27 (37.0)	1.7 (0.5-6.2), 0.394
Moderate/Severe	44/114 (38.6)	31/87 (35.6)	13/27 (48.2)	2.4 (0.7-8.4), 0.165
Fever only				
No	66/116 (56.9)	53/89 (59.6)	13/27 (48.2)	Reference
Yes	50/116 (43.1)	36/89 (40.5)	14/27 (51.9)	1.6 (0.7-3.8), 0.297
Fever, Dyspnea, or Cough				
No	41/116 (35.3)	35/89 (39.3)	6/27 (22.2)	Reference
Yes	75/116 (64.7)	54/89 (60.7)	21/27 (77.8)	2.3 (0.8-6.2), 0.109
Symptom duration				
0-10 days	37/120 (30.8)	30/30 (33.3)	7/30 (23.3)	Reference
11-20 days	59/120 (49.2)	43/90 (47.8)	16/30 (53.3)	1.6 (0.6-4.3), 0.362
				<u> </u>

>20 days	24/120 (20.0)	17/90 (18.9)	7/30 (23.3)	1.8 (0.5-5.9), 0.355
Convalescent testing				
CT value – diagnostic				
swab	53/96 (55.2)	42/71 (59.2)	11/25 (44.0)	1.7 (0.3-8.7), 0.522
<25	28/96 (29.2)	16/71 (22.5)	12/25 (48.0)	4.9 (0.9-25.8), 0.062
25-30	15/96 (15.6)	13/71 (18.3)	2/25 (8.0)	Reference
>30				
Result of convalescent				
swab				
Negative	101/119 (84.9)	75/89 (84.3)	26/30 (86.7)	Reference
Positive	18/119 (15.1)	14/89 (15.7)	4/30 (13.3)	0.8 (0.2-2.7), 0.752
Days Symptom onset to				
Antibody test				
0-35	40/112 (35.7)	31/86 (36.1)	9/26 (34.6)	Reference
35-50	58/112 (51.8)	45/86 (52.3)	13/26 (50.0)	1.1 (0.4-2.8), 0.907
>50	14/112 (12.5)	10/86 (11.6)	4/26 (15.4)	1.5 (0.4-5.8), 0.585
Days from diagnosis to				
Antibody test, median		35 [30-43]	32 [25-40]	1.0 (1.0-1.0), 0.806
[IQR]				

434 ^aMissing data: gender=4, Activity Restriction n=6; Symptomatic n=4; specific symptoms n=8;

435 diagnostic swab n=24; convalescent swab n=1; start of symptoms n=8

436 ^bDiverse gender (n=1) excluded from regression model

437

- 438 Figure titles and legends
- 439
- 440 Figure 1. Convalescent SARS CoV-2 IgG by age category
- 441 The IgG OD ratio at the convalescent visit by age of the participant.

442

- 443 **Figure 2. Convalescent SARS CoV-2 Neutralizing antibody and IgG titers**
- 444 The IgG OD ratio compared to the Neutralizing antibody titer at the convalescent visit.

445

446 Figure 3. Change in SARS CoV-2 IgG levels from Convalescent to Follow-up testing

- 447 The change in IgG OD ratio from the convalescent to the follow-up time points for 35
- 448 participants with available data. Dark blue lines indicate increasing OD ratio, and light blue
- 449 lines indicate the same or decreasing OD ratio.
- 450
- 451 Figure 4. Change in SARS CoV-2 Neutralizing antibody from Convalescent to Follow-
- 452 up testing
- 453 The change in neutralizing antibody titers from the convalescent to the follow-up time points
- 454 for 5 participants with both timepoints available. There are two participants with 1:40 titers at
- 455 both Convalescent and Follow-up timepoints.







